anti-tim-3 antibody sabatolimab hypomethylating agents for high-risk mds & aml
Published 4 years ago • 283 plays • Length 6:51Download video MP4
Download video MP3
Similar videos
-
2:38
advances in immunotherapy for mds: anti-tim-3 & anti-cd47 antibodies and small molecule inhibitors
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:18
the mechanism of action of anti-cd47 antibodies & where these may fit in the mds treatment landscape
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
1:57
gtb-3550 trike for the treatment of mds & aml
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
23:26
yadira soto-feliciano: "mechanisms of transcriptional regulation by chromatin adaptor proteins"
-
3:01
anti-gbm disease - the progression
-
7:43
what are current and emerging aml treatment approaches?
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
0:47
overview of the phase iii enhance trial schema
-
2:21
potential mds targets beyond hmas
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy